- Home
- IPHA vs INBX Comparison
IPHA vs INBX Comparison
Compare IPHA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- INBX
- Stock Information
- Founded
- IPHA 1999
- INBX 2010
- Country
- IPHA France
- INBX United States
- Employees
- IPHA N/A
- INBX 161
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- INBX Health Care
- Exchange
- IPHA Nasdaq
- INBX Nasdaq
- Market Cap
- IPHA 160.1M
- INBX 168.1M
- IPO Year
- IPHA 2019
- INBX 2020
- Fundamental
- Price
- IPHA $1.97
- INBX $11.47
- Analyst Decision
- IPHA Strong Buy
- INBX Hold
- Analyst Count
- IPHA 1
- INBX 1
- Target Price
- IPHA $11.50
- INBX N/A
- AVG Volume (30 Days)
- IPHA 28.5K
- INBX 144.3K
- Earning Date
- IPHA 03-27-2025
- INBX 05-08-2025
- Dividend Yield
- IPHA N/A
- INBX 7.40%
- EPS Growth
- IPHA N/A
- INBX N/A
- EPS
- IPHA N/A
- INBX 112.62
- Revenue
- IPHA $20,831,349.00
- INBX $200,000.00
- Revenue This Year
- IPHA $220.44
- INBX N/A
- Revenue Next Year
- IPHA $81.85
- INBX N/A
- P/E Ratio
- IPHA N/A
- INBX $0.10
- Revenue Growth
- IPHA N/A
- INBX N/A
- 52 Week Low
- IPHA $1.29
- INBX $10.80
- 52 Week High
- IPHA $3.51
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- IPHA 53.30
- INBX 34.68
- Support Level
- IPHA $1.81
- INBX $10.81
- Resistance Level
- IPHA $2.00
- INBX $12.06
- Average True Range (ATR)
- IPHA 0.14
- INBX 1.00
- MACD
- IPHA 0.02
- INBX -0.19
- Stochastic Oscillator
- IPHA 53.76
- INBX 18.52
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.